|Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice|
P Sonveaux, F Végran, T Schroeder, MC Wergin, J Verrax, ZN Rabbani, ...
The Journal of clinical investigation 118 (12), 3930-3942, 2008
|A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer|
A Potti, S Mukherjee, R Petersen, HK Dressman, A Bild, J Koontz, ...
New England Journal of Medicine 355 (6), 570-580, 2006
|Genomic signatures to guide the use of chemotherapeutics|
A Potti, HK Dressman, A Bild, RF Riedel, G Chan, R Sayer, J Cragun, ...
Nature medicine 12 (11), 1294-1300, 2006
|Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non–small-cell lung cancer: Cancer and …|
EE Vokes, JE Herndon, MJ Kelley, MG Cicchetti, N Ramnath, H Neill, ...
Journal of clinical oncology 25 (13), 1698-1704, 2007
|Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action|
PW Finch, X He, MJ Kelley, A Üren, RP Schaudies, NC Popescu, ...
Proceedings of the National Academy of Sciences 94 (13), 6770-6775, 1997
|Screening for lung cancer: a review of the current literature|
PB Bach, MJ Kelley, RC Tate, DC McCrory
Chest 123 (1), 72S-82S, 2003
|A pathway-based classification of human breast cancer|
ML Gatza, JE Lucas, WT Barry, JW Kim, Q Wang, MD Crawford, MB Datto, ...
Proceedings of the National Academy of Sciences 107 (15), 6994-6999, 2010
|Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9|
AK Lalwani, JA Goldstein, MJ Kelley, W Luxford, CM Castelein, ...
The American Journal of Human Genetics 67 (5), 1121-1128, 2000
|Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly|
MJ Kelley, W Jawien, TL Ortel, JF Korczak
Nature genetics 26 (1), 106-108, 2000
|T (brachyury) gene duplication confers major susceptibility to familial chordoma|
XR Yang, D Ng, DA Alcorta, NJ Liebsch, E Sheridan, S Li, AM Goldstein, ...
Nature genetics 41 (11), 1176-1178, 2009
|Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer|
SJ Kim, ZN Rabbani, MW Dewhirst, Z Vujaskovic, RT Vollmer, ...
Lung cancer 49 (3), 325-335, 2005
|Implementation of lung cancer screening in the Veterans Health Administration|
LS Kinsinger, C Anderson, J Kim, M Larson, SH Chan, HA King, KL Rice, ...
JAMA internal medicine 177 (3), 399-406, 2017
|Screening for lung cancer: ACCP evidence-based clinical practice guidelines|
PB Bach, GA Silvestri, M Hanger, JR Jett
Chest 132 (3), 69S-77S, 2007
|Cancer incidence among patients of the US Veterans Affairs health care system|
LL Zullig, GL Jackson, RA Dorn, DT Provenzale, R McNeil, CM Thomas, ...
Military medicine 177 (6), 693-701, 2012
|Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome|
DP Carbone, IF Ciernik, MJ Kelley, MC Smith, S Nadaf, D Kavanaugh, ...
Journal of Clinical Oncology 23 (22), 5099-5107, 2005
|Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A|
Y Zhang, MA Conti, D Malide, F Dong, A Wang, YA Shmist, C Liu, P Zerfas, ...
Blood, The Journal of the American Society of Hematology 119 (1), 238-250, 2012
|Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non–small-cell lung cancer: An analysis of Veterans Health Administration data|
R Santana-Davila, K Devisetty, A Szabo, R Sparapani, C Arce-Lara, ...
Journal of clinical oncology 33 (6), 567, 2015
|Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer|
MJ Kelley, RI Linnoila, IL Avis, MS Georgiadis, F Cuttitta, JL Mulshine, ...
Chest 112 (1), 256-261, 1997
|Differential inactivation of cdkn2 and rb protein in non—Small-cell and small-cell lung cancer cell lines|
MJ Kelley, K Nakagawa, SM Steinberg, JL Mulshine, A Kamb, ...
JNCI: Journal of the National Cancer Institute 87 (10), 756-761, 1995
|Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial …|
EE Vokes, JE Herndon, MJ Kelley, D Watson, MG Cicchetti, MR Green
Journal of Clinical Oncology 22 (14_suppl), 7005-7005, 2004